Synopsis
MediCom Oncology Clinical Pearl Podcasts provide practical, evidence-based recommendations on real-world issues in the clinical setting, in under three minutes. Leading experts and academic faculty from top research and practice institutions provide guidance to community-based healthcare providers, including oncologists, pharmacists and nurses. Podcasts are brought to you by MediCom Worldwide, Inc., an accredited, independent medical education company.Podcasts are intended for licensed adult healthcare professionals (HCPs). HCPs should exercise professional judgment in evaluating content, and confirm information before implementing treatment or practice-related changes. Podcasts do not provide medical advice to patients.
Episodes
-
![Third-generation FLT3 inhibitors in clinical development]()
Third-generation FLT3 inhibitors in clinical development
26/10/2018 Duration: 02minDr. Perl provides a brief summary of what is on the horizon for FLT3 inhibitors in AML.
-
![CAR T case study in acute myeloid leukemia]()
CAR T case study in acute myeloid leukemia
05/10/2018 Duration: 05minDr. Sallman describes a patient case demonstrating promise in the further study and potential use of CAR T-cell therapy for patients with AML.
-
![Key considerations when prescribing midostaurin with a strong CYP3A4 inhibi]()
Key considerations when prescribing midostaurin with a strong CYP3A4 inhibi
05/10/2018 Duration: 02minDr. Perl gives guidance on providing optimal patient therapy when prescribing midostaurin with a strong CYP3A4 inhibitor.
-
![How to proceed with a patient who presents with idiopathic cytopenia of undetermined significance]()
How to proceed with a patient who presents with idiopathic cytopenia of undetermined significance
20/03/2018 Duration: 03minIn this audio activity, Dr. Goldberg describes his approach to patients with idiopathic or clonal cytopenias of undetermined significance (ICUS and CCUS).
-
![When to consider iron chelation therapy for a transplant-eligible patient]()
When to consider iron chelation therapy for a transplant-eligible patient
20/03/2018 Duration: 03minListen as Dr. Goldberg explains his approach to iron chelation therapy in patients who are, or may be within the next 5-10 years, eligible for transplant.
-
![53-year-old woman presenting with severe fatigue and bruising]()
53-year-old woman presenting with severe fatigue and bruising
20/03/2018 Duration: 03minHematopathologist Dr. Khoury presents a case snapshot showing the complexities of diagnosing AML, describing the importance of morphology, flow cytometry, cytogenetics, and molecular diagnostics.
-
![New subcategories of pancreatic cancer allow for a biomarker-driven approach to therapy]()
New subcategories of pancreatic cancer allow for a biomarker-driven approach to therapy
05/01/2018 Duration: 04minDr. O'Reilly discusses the new subcategories of pancreatic cancer that have emerged, and which are laying the groundwork for a biomarker-driven approach to therapy.
-
![What are the unique aspects of pancreas cancer that lead to the development of novel therapeutics?]()
What are the unique aspects of pancreas cancer that lead to the development of novel therapeutics?
05/01/2018 Duration: 02minDr. O'Reilly discusses the unique pathophysiology of pancreas cancer that must be considered in the development of novel therapeutics.
-
![Predictors of response to lenalidomide in a non-del(5q) MDS patient]()
Predictors of response to lenalidomide in a non-del(5q) MDS patient
05/01/2018 Duration: 03minListen as Dr. Goldberg discusses, in just under two minutes, the predictors of response to lenalidomide in a non-del(5q) MDS patient.
-
![What are the pros and cons of radiation therapy?]()
What are the pros and cons of radiation therapy?
21/12/2017 Duration: 02minListen as Dr. Matasar discusses the pros and cons of radiation therapy, and who should be offered this therapy.
-
![What defines high-quality survivorship care for patients treated for classical Hodgkin lymphoma?]()
What defines high-quality survivorship care for patients treated for classical Hodgkin lymphoma?
30/11/2017 Duration: 03minListen as Dr. Matasar discusses survivorship care for patients who have been treated for classical Hodgkin lymphoma, including late effects of treatment.
-
![Second primary malignancies associated with lenalidomide maintenance]()
Second primary malignancies associated with lenalidomide maintenance
30/11/2017 Duration: 02minDr. Jacob Laubach discusses second primary malignancies associated with lenalidomide maintenance in the transplant and post-transplant setting.
-
![Impact of consolidation therapy in patients post-transplant]()
Impact of consolidation therapy in patients post-transplant
30/11/2017 Duration: 03minDr. Laubach discusses the impact of consolidation therapy in patients post-transplant, referencing results of the CTN StaMINA trial.
-
![Bortezomib as an alternate strategy for maintenance therapy.]()
Bortezomib as an alternate strategy for maintenance therapy.
23/10/2017 Duration: 02minDr. Jacob Laubach discusses bortezomib as an alternate strategy to lenalidomide for maintenance therapy in patients with multiple myeloma.
-
![What may be the future role for brentuximab vedotin in newly diagnosed Hodgkin lymphoma?]()
What may be the future role for brentuximab vedotin in newly diagnosed Hodgkin lymphoma?
23/10/2017 Duration: 02minListen as Dr. Matasar discusses the future role of brentuximab vedotin in patients with newly diagnosed classical Hodgkin lymphoma.
-
![Has MRD testing become a standard of care in multiple myeloma?]()
Has MRD testing become a standard of care in multiple myeloma?
23/10/2017 Duration: 03minDr. Ruben Niesvizky discusses MRD testing and how it has become a standard of care in multiple myeloma, as well as future directions in MRD testing that will improve outcomes in these patients.
-
![The Precision Promise [SM] Initiative: What is it designed to achieve?]()
The Precision Promise [SM] Initiative: What is it designed to achieve?
27/09/2017 Duration: 04minDr. O'Reilly provides an insightful overview of how the emerging use of precision medicine and the Precision Promise [SM] initiative will impact the new drug approval process in pancreatic cancer.
-
![Enasidenib in mutant-IDH2 R/R AML: Results of a phase 1 dose-escalation and expansion study]()
Enasidenib in mutant-IDH2 R/R AML: Results of a phase 1 dose-escalation and expansion study
27/09/2017 Duration: 08minDr. Eytan Stein provides a brief update on phase 1 arms of a trial studying the effectiveness of enasidenib in patients with relapsed and refractory AML and an IDH2 mutation.
-
![What are the optimal imaging methods to determine extent of bone disease in newly diagnosed MM?]()
What are the optimal imaging methods to determine extent of bone disease in newly diagnosed MM?
27/09/2017 Duration: 03minDr. Ruben Niesvizky discusses newer approaches for imaging in patients who have multiple myeloma with bone disease, including the benefits of combining modalities such MRI and PET scan.
-
![The standard of care for patients receiving lenalidomide or thalidomide who are at high risk for VTE]()
The standard of care for patients receiving lenalidomide or thalidomide who are at high risk for VTE
27/09/2017 Duration: 03minDr. Ruben Niesvizky discusses clinical approaches to managing the risk of developing VTE in myeloma patients receiving immunomodulating agents such as lenalidomide or thalidomide.
![The Precision Promise [SM] Initiative: What is it designed to achieve?](http://media3.ubook.com/catalog/book-cover-image/319115/200x200/1C4DBF52-5B10-994B-897D-3B886BB6E335.jpg)
